Chaudhary Shivang, Baumer Meghan, Upton Laura, Ong Samantha, Smith Kristin, West Daniel, Kilian Adam
Saint Louis University School of Medicine, St. Louis, Missouri.
ACR Open Rheumatol. 2025 Jan;7(1):e11792. doi: 10.1002/acr2.11792.
Dermatomyositis is an idiopathic inflammatory myopathy which can present with distinctive skin features. Despite the many treatment modalities for the treatment of dermatomyositis some patients remain refractory to treatment. We present a case of a 38-year-old man with recalcitrant dermatomyositis who was successfully treated with the interferon α receptor 1-inhibiting monoclonal antibody anifrolumab. Many studies have shown a correlation between dermatomyositis disease activity and the type 1 interferon pathway activity. We believe anifrolumab may be a promising option for severe cutaneous dermatomyositis.
皮肌炎是一种特发性炎性肌病，可伴有独特的皮肤表现。尽管有多种治疗皮肌炎的方法，但仍有一些患者对治疗无效。我们报告一例38岁顽固性皮肌炎男性患者，他接受干扰素α受体1抑制性单克隆抗体阿尼鲁单抗治疗取得成功。许多研究表明皮肌炎疾病活动与1型干扰素通路活性之间存在关联。我们认为阿尼鲁单抗可能是重度皮肤型皮肌炎的一个有前景的治疗选择。
